Quantcast

Health Care
Valeant Acquires Targretin for $65M

Targretin is used to treat skin legions caused by cutaneous T-cell lymphoma

Montreal-based Valeant Pharmaceuticals International Inc. (NYSE: VRX) has acquired the U.S. rights to Targretin, medication used to treat skin problems, for $65 million.

The company bought the rights from Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co. Ltd, which is based in Japan. 

Targretin treats skin problems caused by cutaneous T-cell lymphoma, which can cause skin legions. The medication comes in pill and gel forms.

In September, Valeant agreed to buy Medicis Pharmaceutical Corp. (NYSE: MRX) for $2.6 billion. 

 

For more information on related topics, visit the following: